From: Evaluation of B-type Natriuretic Peptide for validation of a heart failure register in primary care
 | Echocardiogram not consistent with heart failure (n = 24) | Echocardiogram consistent with heart failure (n = 32) | p value |
---|---|---|---|
Age – mean (SD) | 75.4 (7.2) | 78.3 (8.4) | 0.184 (t-test) |
Male gender | 13 (54.2%) | 13 (40.6%) | 0.315 |
Ischaemic heart disease | 7 (29.2%) | 16 (50.0%) | 0.117 |
Hypertension | 12 (50.0%) | 14 (43.8%) | 0.643 |
Diabetes | 4 (16.7%) | 9 (28.1%) | 0.315 |
Atrial fibrillation | 3 (12.5%) | 6 (18.8%) | 0.529 |
Peripheral vascular disease | 2 (8.3%) | 2 (6.3%) | 0.765 |
Chronic airflow limitation | 6 (25.0%) | 5 (15.6%) | 0.382 |
Diuretic | 21 (87.5%) | 24 (75.0%) | 0.244 |
Angiotensin converting enzyme inhibitor or Angiotensin receptor blocker | 14 (58.3%) | 23 (71.9%) | 0.290 |
Beta-blocker | 2 (8.3%) | 8 (25.0%) | 0.107 |
Statin | 9 (37.5%) | 14 (43.8%) | 0.638 |
Abnormal ECG | 13 (54.2%) | 27 (84.4%) | 0.013 |
BNP (pmol/l) median (interquartile range) | 11.7 (20.0) | 32.75 (35.8) | 0.010 (Mann-Whitney test) |